Author

R. Ella

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Microbiology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:host-pathogen & immune response· 4 Organism:human· 3 Organism:mouse· 1 Assay:proteomics· 1 Organism:rat· 1

Frequent Co-Authors

N. Gupta· 4 shared P. Abraham· 4 shared B. Bhargava· 3 shared P. Yadav· 3 shared S. Panda· 3 shared A. M. Shete· 2 shared D. Y. Patil· 2 shared G. Deshpande· 2 shared

Activity by Year

2020-2021 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 44 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersMicrobiology

N. Gupta

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Neutralization against B.1.351 and B.1.617.2 with sera of COVID-19 recovered cases and vaccinees of BBV152

P. D. Yadav, G. Sapkal, R. Ella, R. R. Sahay, D. A. Nyayanit, D. Y. Patil, G. Deshpande, A. M. Shete, N. Gupta, V. K. Mohan, P. Abraham, S. Panda, B. Bhargava

This study assesses the neutralization efficacy of sera from COVID-19 recovered cases and BBV152 vaccinees against SARS-CoV-2 variants B.1.351 and B.1.617.2, showing reduced titers but still protective responses.

bioRxiv · Jun 5, 2021 · PreprintMicrobiology

Neutralization of B.1.1.28 P2 variant with sera of natural SARS-CoV-2 infection and recipients of BBV152 vaccine

G. Sapkal, P. Yadav, R. Ella, P. Abraham, D. Patil, N. Gupta, S. Panda, K. M. V, B. Bhargava

This study evaluates the neutralizing efficacy of B.1.1.28.2 variant against sera from natural infection and BBV152 vaccine recipients, showing reduced neutralization compared to D614G.

bioRxiv · Apr 30, 2021 · PreprintMicrobiology

Neutralization of variant under investigation B.1.617 with sera of BBV152 vaccinees

P. Yadav, G. N. Sapkal, P. Abraham, R. Ella, G. Deshpande, D. Y. Patil, D. Nyayanit, N. Gupta, R. R. Sahay, A. M. Shete, S. Panda, B. Bhargava, V. K. Mohan

The paper assesses the neutralizing ability of sera from BBV152 vaccinees and convalescent COVID-19 patients against B.1.617 variants.

bioRxiv · Apr 23, 2021Immunology

Evaluation of Safety and Immunogenicity of an Adjuvanted, TH-1 Skewed, Whole Virion Inactivated SARS-CoV-2 Vaccine - BBV152

B. Ganneru, H. Jogdand, V. K. Dharam, N. Reddy, S. D. Prasad, S. Vellimudu, K. M. Ella, R. Ravikrishnan, A. Awasthi, J. Jose, P. Rao, D. Kumar, R. Ella, P. Abraham, P. Yadav, , K. V. Mohan

This study evaluates the safety and immunogenicity of a SARS-CoV-2 vaccine BBV152 in mice, rats, and rabbits, showing high antibody titers and Th1-biased responses with the TLR7/8 agonist adjuvant.

bioRxiv · Sep 9, 2020 · PreprintImmunology